Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
Akero Therapeutics (Nasdaq: AKRO), a clinical-stage company focused on developing treatments for serious metabolic diseases, has announced its participation in the H.C. Wainwright 8th Annual MASH Virtual Conference. The company's management will engage in a fireside chat on Monday, October 7, 2024, at 11:00 a.m. E.T.
Interested parties can access a live webcast of the presentation through the investor relations section of Akero's website at www.akerotx.com. For those unable to attend the live event, an archived replay will be made available on the company's website following the presentation.
Akero Therapeutics (Nasdaq: AKRO), un'azienda in fase clinica focalizzata sullo sviluppo di trattamenti per gravi malattie metaboliche, ha annunciato la sua partecipazione alla 8ª Conferenza Virtuale Annuale MASH di H.C. Wainwright. La direzione dell'azienda parteciperà a una chat informale lunedì, 7 ottobre 2024, alle 11:00 E.T.
Le parti interessate possono accedere a una webcast in diretta della presentazione attraverso la sezione relazioni con gli investitori del sito di Akero all'indirizzo www.akerotx.com. Per coloro che non possono partecipare all'evento dal vivo, un replay archiviato sarà reso disponibile sul sito dell'azienda dopo la presentazione.
Akero Therapeutics (Nasdaq: AKRO), una empresa en etapa clínica centrada en el desarrollo de tratamientos para enfermedades metabólicas graves, ha anunciado su participación en la 8ª Conferencia Virtual Anual MASH de H.C. Wainwright. La dirección de la empresa participará en una charla informal el lunes, 7 de octubre de 2024, a las 11:00 a.m. E.T.
Las partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección de relaciones con inversores del sitio web de Akero en www.akerotx.com. Para aquellos que no puedan asistir al evento en vivo, se dispondrá de una repetición archivada en el sitio web de la empresa después de la presentación.
Akero Therapeutics (Nasdaq: AKRO)는 심각한 대사 질환 치료제 개발에 집중하는 임상 단계의 회사로서 H.C. Wainwright 제8회 연례 MASH 가상 회의에 참가한다고 발표했습니다. 회사 경영진은 2024년 10월 7일 월요일, 오전 11시 E.T.에 화상 대화에 참여할 예정입니다.
관심 있는 분들은 Akero의 웹사이트 투자자 관계 섹션을 통해 라이브 웹 캐스트를 시청할 수 있습니다: www.akerotx.com. 실시간 행사에 참석할 수 없는 분들을 위해, 발표 후 회사 웹사이트에 아카이브된 재생이 제공될 예정입니다.
Akero Therapeutics (Nasdaq: AKRO), une entreprise en phase clinique axée sur le développement de traitements pour des maladies métaboliques graves, a annoncé sa participation à la 8ème Conférence Virtuelle Annuelle MASH de H.C. Wainwright. La direction de l’entreprise participera à une discussion informelle le lundi 7 octobre 2024, à 11h00 E.T.
Les parties intéressées peuvent accéder à un webcast en direct de la présentation via la section relations investisseurs du site web d'Akero à www.akerotx.com. Pour ceux qui ne peuvent pas assister à l'événement en direct, un rediffusion archivée sera mise à disposition sur le site de l’entreprise après la présentation.
Akero Therapeutics (Nasdaq: AKRO), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für schwere Stoffwechselkrankheiten konzentriert, hat seine Teilnahme an der 8. jährlichen MASH-Virtual-Konferenz von H.C. Wainwright angekündigt. Das Management des Unternehmens wird am Montag, den 7. Oktober 2024, um 11:00 Uhr E.T. an einem informellen Gespräch teilnehmen.
Interessierte Parteien können über den Bereich Investor Relations der Akero-Website auf ein Live-Webcast der Präsentation zugreifen unter www.akerotx.com. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird eine archivierte Wiederholung nach der Präsentation auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference on Monday, October 7, 2024, at 11:00 a.m. E.T.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4) in which patients have been treated for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the H.C. Wainwright MASH Virtual Conference?
How can I watch Akero Therapeutics' (AKRO) presentation at the H.C. Wainwright conference?
Will there be a replay available of Akero Therapeutics' (AKRO) presentation at the H.C. Wainwright conference?
What type of company is Akero Therapeutics (AKRO)?
